//
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin?
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)
ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art Review